FDA Authorizes Updated COVID-19 Vaccines Targeting XFG Variant for 2026-2027

The FDA has approved supplemental Biologics License Applications for the 2026-2027 COVID-19 vaccine formulas from Moderna (Spikevax and mNEXSPIKE), Pfizer-BioNTech (Comirnaty XFG), and Novavax (Nuvaxovid). These updated vaccines are designed to protect against the JN1-lineage XFG subvariant of SARS-CoV-2, with specific indications for different age and risk groups.